BJP Handbook for Psychiatric Trainees
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obrocki, J.
Right arrow Articles by Schiemann, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obrocki, J.
Right arrow Articles by Schiemann, T.

The British Journal of Psychiatry 175: 186-188 (1999)
© 1999 The Royal College of Psychiatrists

Ecstasy--long-term effects on the human central nervous system revealed by positron emission tomography

J Obrocki, R Buchert, O Vaterlein, R Thomasius, W Beyer and T Schiemann
Department of Psychiatry and Psychotherapy, University Hospital, Hamburg, Germany.

BACKGROUND: The main psychotropic agent of the popular illicit drug ecstasy is 3,4-methylenedioxymethamphetamine (MDMA). In the light of animal studies and examinations of human cerebrospinal fluid, MDMA is suspected of causing neurotoxic lesions to the serotonergic system. AIMS: To postulate a relationship between ecstasy use and lasting alterations to the cerebral glucose metabolic rate. METHOD: Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) was performed on seven ecstasy users and seven subjects without any known history of illicit drug use. Data were compared for a limited number of brain regions. RESULTS: By comparison with the control group, the glucose metabolic uptake of the ecstasy user group was altered within the amygdala, hippocampus and Brodmann's area II. CONCLUSIONS: The results suggest the possibility that ecstasy use has lasting effects on central neuronal activity in humans.


This article has been cited by other articles:


Home page
 FASEB J.Home page
W. Jeng, A. Ramkissoon, T. Parman, and P. G. Wells
Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration
FASEB J, April 1, 2006; 20(6): 638 - 650.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
N. Easton and C. A. Marsden
Ecstasy: Are animal data consistent between species and can they translate to humans?
J Psychopharmacol, March 1, 2006; 20(2): 194 - 210.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
A. C. Parrott
Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
J Psychopharmacol, January 1, 2005; 19(1): 71 - 83.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
M. C. Jockers-ScheruBl, U. Matthies, H. Danker-Hopfe, U. E. Lang, R. Mahlberg, and R. Hellweg
Chronic Cannabis Abuse Raises Nerve Growth Factor Serum Concentrations in Drug-Naive Schizophrenic Patients
J Psychopharmacol, December 1, 2003; 17(4): 439 - 445.
[Abstract] [PDF]

Home page
 JNMHome page
R. Buchert, R. Thomasius, B. Nebeling, K. Petersen, J. Obrocki, L. Jenicke, F. Wilke, L. Wartberg, P. Zapletalova, and M. Clausen
Long-Term Effects of "Ecstasy" Use on Serotonin Transporters of the Brain Investigated by PET
J. Nucl. Med., March 1, 2003; 44(3): 375 - 384.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
R. A. Hurley, L. Reneman, and K. H. Taber
Ecstasy in the Brain: A Model for Neuroimaging
J Neuropsychiatry Clin Neurosci, May 1, 2002; 14(2): 125 - 129.
[Full Text] [PDF]

Home page
 CMAJHome page
H. Kalant
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs
Can. Med. Assoc. J., October 1, 2001; 165(7): 917 - 928.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1999 The Royal College of Psychiatrists.